SEC restatements
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. has 2 revised figures in later SEC filings: annual figures whose value in a later filing differs from the value on record first. Each revision below links to both filings.
CIK 0001652130
Most recent revisions
Newest 2 of 2 · as filed · by the latest filing stating each revision
| Figure | On record first | Revised |
|---|---|---|
| Net incomePeriod ended Dec 31, 2019 | $-99.53MFiled Feb 27, 2020 (opens EDGAR in a new tab) | $-474.19MFiled Feb 23, 2023 (opens EDGAR in a new tab) |
| Shares outstandingPeriod ended Dec 31, 2020 | 50.20M sharesFiled Feb 26, 2021 (opens EDGAR in a new tab) | 66.23M sharesFiled Feb 24, 2022 (opens EDGAR in a new tab) |
A revised figure is not by itself a correction of an error. Companies re-present prior figures for ordinary reasons too, such as a discontinued business, a merger or a new accounting standard. The value on record first is the earliest filing we hold that states the figure; the revised value is the latest revised value on record, linked to the latest filing that states it.
Programmatic access
Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.
- Every revised figure for this company, with both values and both filings (Analyst)
- curlcurl -H "X-Api-Key: $DISTILL_API_KEY" \https://api.distillmarkets.com/api/v1/sec/revisions/NTLA
MCP tool:
get_revisions ticker=NTLA
Not investment advice. Figures are shown as filed with the SEC; each one links to the filing it came from.